Cara Therapeutics $CARA reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.58) by 10.34 percent. This is a 20.93 percent decrease over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $5.5 million which beat the analyst consensus estimate of $2.67 million by 105.99 percent.